The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...

The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...